Pharmaceuticals & Therapeutics

Biotech firm ProJenX reports its novel ALS drug, prosetin, is safe and hits key targets in early trials, offering a new beacon of hope for the disease.

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

Pasithea Therapeutics is expanding its NF1 trial for PAS-004, a move that signals a deeper strategic commitment to outmaneuvering competitors and meeting a critical unmet medical need.

GXO Logistics' entry into Italy's Distretto Aerospaziale Piemonte is more than a membership; it's a strategic move to secure Europe's defense supply lines.

The appointment of drug development veteran Dr. Aaron Koenig at Syremis Therapeutics is more than a new hire; it's a strategic play in the high-stakes race to redefine mental health treatment.

The company behind the first FDA-cleared birth control app is expanding into a holistic wellness platform, a strategic move that could redefine the FemTech market.

As Latus Bio advances its Huntington's therapy to clinic, new CBO Bethany Mancilla brings a history of high-value deals to fuel the company's growth.

With a $22M Series A and a factory-focused plan, Foundation Alloy is moving to scale a melt-free metallurgy process that could redefine global manufacturing.

A new silicon battery from Coreshell promises a 30% performance boost and a domestic supply chain, aiming to secure U.S. military technology from foreign risk.

As the AI boom pushes data center energy demand to its limits, Cipher Digital's hire of ERCOT veteran Bill Blevins is a masterstroke in a new high-stakes game.

Devices like MyoGlow aren't just beauty tools; they represent a major economic disruption. We dissect the tech and market forces bringing thousand-dollar med spa treatments into the home.

As USANA marks 10 years of its World Service Week, a closer look reveals how its direct-selling network is strategically engineered to power a global charity.

Newcore Gold's latest deep drilling at its Enchi project in Ghana extends high-grade gold zones, signaling major resource growth ahead of a pivotal study.

A new European patent for 'smart' battery material isn't just tech—it's a strategic move to dominate Europe's high-stakes electrification market.

As Grown Rogue restarts a dormant Illinois facility, it’s not just planting seeds—it’s testing a capital-efficient strategy for winning in a crowded market.

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.

A simple blood test for lung cancer completes key validation, signaling potential disruption for the diagnostics market and major savings for healthcare systems.

A short-seller report alleges ADMA faked 20% growth, triggering a 40% stock collapse and a securities fraud lawsuit with an August 10 investor deadline.

A consumer-led purity crusade is fueling a projected half-billion-dollar bio-vanillin market, forcing a high-stakes pivot from synthetic to sustainable.

A 125-year-old pest control giant is funding a new generation of scientists, betting that the secrets of insects can solve our biggest future challenges.